Trial · NCT03088878
Adverse events924
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 924
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | MCL Phase 1b, Part 1: 2mg/kg | 1 | 3 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | MCL Phase 1b, Part 1: 4mg/kg | 1 | 3 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | MCL Phase 1b, Part 1: 8mg/kg | 0 | 3 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | MCL Phase 1b, Part 1: 16 mg/kg | 2 | 3 | 3 |
| other | Anaemia | Blood and lymphatic system disorders | MCL Phase 1b, Part 2: 600 mg | 6 | 21 | 8 |
| other | Anaemia | Blood and lymphatic system disorders | CLL Phase 1b, Part 1: 2 mg/kg | 0 | 3 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | CLL Phase 1b, Part 1: 4 mg/kg | 1 | 3 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | CLL Phase 1b, Part 1: 8 mg/kg | 0 | 3 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | CLL Phase 1b, Part 1: 16 mg/kg | 1 | 3 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | CLL Phase 1b, Part 1: 300 mg | 1 | 3 | 2 |
| other | Anaemia | Blood and lymphatic system disorders | CLL Phase 1b, Part 1: 600 mg | 1 | 3 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | CLL Phase 1b, Part 2: 600 mg | 3 | 16 | 3 |
| other | Anaemia | Blood and lymphatic system disorders | CLL Phase 2, Part 3: 600 mg | 3 | 18 | 6 |
| other | Anaemia | Blood and lymphatic system disorders | CLL Phase 2, Part 3: Ibrutinib Alone | 1 | 10 | 1 |
| other | Leukocytosis | Blood and lymphatic system disorders | MCL Phase 1b, Part 1: 2mg/kg | 0 | 3 | 0 |
| other | Leukocytosis | Blood and lymphatic system disorders | MCL Phase 1b, Part 1: 4mg/kg | 0 | 3 | 0 |
| other | Leukocytosis | Blood and lymphatic system disorders | MCL Phase 1b, Part 1: 8mg/kg | 0 | 3 | 0 |
| other | Leukocytosis | Blood and lymphatic system disorders | MCL Phase 1b, Part 1: 16 mg/kg | 0 | 3 | 0 |
| other | Leukocytosis | Blood and lymphatic system disorders | MCL Phase 1b, Part 2: 600 mg | 2 | 21 | 2 |
| other | Leukocytosis | Blood and lymphatic system disorders | CLL Phase 1b, Part 1: 2 mg/kg | 0 | 3 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03088878/events